LONDON, March 4 (Reuters) - New research suggesting the blood thinner Plavix interacts badly with common heartburn drugs is a potential threat to AstraZeneca’s (AZN.L) top-seller Nexium rather than Sanofi-Aventis’s (SASY.PA) Plavix, analysts said.
LONDON, March 4 (Reuters) - New research suggesting the blood thinner Plavix interacts badly with common heartburn drugs is a potential threat to AstraZeneca’s (AZN.L) top-seller Nexium rather than Sanofi-Aventis’s (SASY.PA) Plavix, analysts said.
